Academic Research Intelligence

The literature advances
every day.

Novarum Scholar scans thousands of journals and preprint servers daily. We surface the papers that matter to your research — with plain-language summaries — delivered on your schedule.

Begin reading smarter View plans

Sources includePubMedarXivOpenAlexEurope PMCbioRxiv

How It Works

Three steps. Then it runs itself.

Define your topics

Enter any research keyword — a disease, molecule, method, or field. As specific or broad as your work demands.

Set your cadence

Choose how often you want your digest — once a week, three times, or daily. We work on your schedule.

Receive your digest

A clean, readable email arrives with AI-written summaries and direct links to every paper. Nothing more.

What You Get

Built for serious researchers.

The literature is vast. Your time is not. Novarum Scholar does the scanning so you can focus on the science.

Start for free

GRAPHIC PLACEHOLDER

AI-Written Summaries

Every paper gets a concise, accurate summary. Understand the finding in 30 seconds.

No Duplicate Articles

We track every paper we've sent you. You'll never see the same article twice.

Preprints, Clearly Labeled

We include arXiv, bioRxiv, medRxiv — always marked so you know what's peer-reviewed.

Five Major Databases

OpenAlex, PubMed, Europe PMC, arXiv, and Semantic Scholar. Full coverage.

Direct Links to Source

One click to the paper. No paywalls added — just the DOI or open-access link.

Sample Issue

This is what arrives in your inbox.

Novarum Scholar — Research Digest

New papers in CRISPR gene editing

Tuesday, April 21, 2026 · 3 new articles

Nature Biotechnology· Apr 19, 2026

High-fidelity prime editing in human hematopoietic stem cells

Researchers demonstrate a refined prime editing approach achieving over 90% efficiency in HSCs with minimal off-target effects, advancing CRISPR-based therapies for sickle cell disease and beta-thalassemia.

Read paper

bioRxiv· Apr 20, 2026PREPRINT

Compact Cas9 variants enable efficient in vivo delivery via AAV vectors

A new family of miniaturized Cas9 nucleases fits within AAV packaging limits while maintaining editing efficacy, overcoming a major barrier for in vivo therapeutic delivery.

Read paper

+ 1 more article in this issue

Pricing